Efferocytosis: Signaling Pathways and New Therapeutic Strategies for Diseases

Abstract

Efferocytosis—the phagocytic clearance of apoptotic cells (ACs)—is essential for maintaining tissue homeostasis, immune tolerance, and inflammation resolution. Beyond classic receptor-mediated recognition, this process drives phagocyte metabolic reprogramming to actively facilitate tissue repair. Consequently, defective efferocytosis serves as a core pathogenic mechanism across major human diseases. This review outlines the molecular and metabolic foundations of efferocytosis and defines four universal hallmarks of its dysfunction: senescence-driven impairment, unresolved inflammation, loss of immune tolerance, and fibrotic tissue repair. Subsequent sections explore how these defects manifest in cardiovascular, autoimmune, and neurodegenerative conditions, as well as cancer. Because efferocytosis exhibits a dual pathophysiological nature, therapeutic interventions must be highly disease-specific. Enhancing apoptotic clearance can effectively resolve chronic inflammatory and fibrotic conditions. Conversely, because tumors hijack these same pathways to build immunosuppressive microenvironments, inhibiting efferocytosis remains a critical strategy in oncology. The synthesis of these divergent roles informs a “context-dependent directionality” framework to guide the clinical translation of efferocytosis-targeted precision therapies.

Keywords

efferocytosis / immune tolerance / inflammation resolution / metabolic reprogramming / precision therapy

References

[1] A. C. Doran, A. Yurdagul, and I. Tabas, “Efferocytosis in Health and Disease,” Nature Reviews Immunology 20, no. 4 (2020): 254–267.

[2] P. Mehrotra and K. S. Ravichandran, “Drugging the Efferocytosis Process: Concepts and Opportunities,” Nature Reviews Drug Discovery 21, no. 8 (2022): 601–620.

[3] C. Li, Y. Yang, F. Zhou, et al., “Efferocytosis in Health and Disease,” MedComm 6, no. 12 (2025): e70546.

[4] I. K. H. Poon and K. S. Ravichandran, “Targeting Efferocytosis in Inflammaging,” Annual Review of Pharmacology and Toxicology 64 (2024): 339–357.

[5] B. Zhang, Y. Zou, Z. Yuan, et al., “Efferocytosis: The Resolution of Inflammation in Cardiovascular and Cerebrovascular Disease,” Frontiers in Immunology 15 (2024): 1485222.

[6] M. Schilperoort, D. Ngai, S. R. Sukka, et al., “The Role of Efferocytosis-Fueled Macrophage Metabolism in the Resolution of Inflammation,” Immunological Reviews 319, no. 1 (2023): 65–80.

[7] A. Tajbakhsh and A. Movahedpour, “The Complex Roles of Efferocytosis in Cancer Development, Metastasis, and Treatment,” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 140 (2021): 111776.

[8] M. R. Elliott, F. B. Chekeni, P. C. Trampont, et al., “Nucleotides Released by Apoptotic Cells Act as a Find-Me Signal to Promote Phagocytic Clearance,” Nature 461, no. 7261 (2009): 282–286.

[9] C. B. Medina and K. S. Ravichandran, “Do Not Let Death Do Us Part: ‘Find-Me’ Signals in Communication Between Dying Cells and the Phagocytes,” Cell Death and Differentiation 23, no. 6 (2016): 979–989.

[10] L. A. Truman, C. A. Ford, M. Pasikowska, et al., “CX3CL1/Fractalkine Is Released From Apoptotic Lymphocytes to Stimulate Macrophage Chemotaxis,” Blood 112, no. 13 (2008): 5026–5036.

[11] I. K. Poon, C. D. Lucas, A. G. Rossi, and K. S. Ravichandran, “Apoptotic Cell Clearance: Basic Biology and Therapeutic Potential,” Nature Reviews Immunology 14, no. 3 (2014): 166–180.

[12] V. A. Fadok, D. L. Bratton, S. C. Frasch, et al., “The Role of Phosphatidylserine in Recognition of Apoptotic Cells by Phagocytes,” Cell Death and Differentiation 5, no. 7 (1998): 551–562.

[13] M. Miyanishi, K. Tada, M. Koike, et al., “Identification of Tim4 as a Phosphatidylserine Receptor,” Nature 450, no. 7168 (2007): 435–439.

[14] M. Fricker, J. J. Neher, J. W. Zhao, et al., “MFG-E8 Mediates Primary Phagocytosis of Viable Neurons During Neuroinflammation,” Journal of Neuroscience 32, no. 8 (2012): 2657–2666.

[15] K. Geng, S. Kumar, S. G. Kimani, et al., “Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6,” Frontiers in Immunology 8 (2017): 1521.

[16] Z. Liu, Y. Li, Y. Ren, et al., “Efferocytosis: The Janus-Faced Gatekeeper of Aging and Tumor Fate,” Aging Cell 24, no. 2 (2025): e14467.

[17] J. H. van der Meer, T. van der Poll, and C. van 't Veer, “TAM Receptors, Gas6, and Protein S: Roles in Inflammation and Hemostasis,” Blood 123, no. 16 (2014): 2460–2469.

[18] D. Park, A. C. Tosello-Trampont, M. R. Elliott, et al., “BAI1 Is an Engulfment Receptor for Apoptotic Cells Upstream of the ELMO/Dock180/Rac Module,” Nature 450, no. 7168 (2007): 430–434.

[19] E. Boada-Romero, J. Martinez, B. L. Heckmann, and D. R. Green, “The Clearance of Dead Cells by Efferocytosis,” Nature Reviews Molecular Cell Biology 21, no. 7 (2020): 398–414.

[20] M. Zhang, T. K. Johnson-Stephenson, and W. Wang, “Mesenchymal Stem Cell-Derived Exosome-Educated Macrophages Alleviate Systemic Lupus Erythematosus by Promoting Efferocytosis and Recruitment of IL-17(+) Regulatory T Cell,” Stem Cell Research & Therapy 13, no. 1 (2022): 484.

[21] M. Kawano and S. Nagata, “Efferocytosis and Autoimmune Disease,” International Immunology 30, no. 12 (2018): 551–558.

[22] L. Rochette, G. Dogon, E. Rigal, et al., “Interplay Between Efferocytosis and Atherosclerosis,” Archives of Cardiovascular Diseases 116, no. 10 (2023): 474–484.

[23] B. Ravishankar, H. Liu, R. Shinde, et al., “The Amino Acid Sensor GCN2 Inhibits Inflammatory Responses to Apoptotic Cells Promoting Tolerance and Suppressing Systemic Autoimmunity,” Proceedings of the National Academy of Sciences of the United States of America 112, no. 34 (2015): 10774–10779.

[24] K. Yao, J. Fang, Y. L. Yin, et al., “Tryptophan Metabolism in Animals: Important Roles in Nutrition and Health,” Frontiers in Bioscience 3, no. 1 (2011): 286–297.

[25] A. A. Badawy, “Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects,” International Journal of Tryptophan Research: IJTR 10 (2017): 1178646917691938.

[26] A. Yurdagul, M. Subramanian, and X. Wang, “Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury,” Cell Metabolism 31, no. 3 (2020): 10.

[27] P. B. Ampomah, B. Cai, S. R. Sukka, et al., “Macrophages Use Apoptotic Cell-Derived Methionine and DNMT3A During Efferocytosis to Promote Tissue Resolution,” Nature Metabolism 4, no. 4 (2022): 444–457.

[28] A. L. McCubbrey, S. A. McManus, J. D. McClendon, et al., “Polyamine Import and Accumulation Causes Immunomodulation in Macrophages Engulfing Apoptotic Cells,” Cell Reports 38, no. 2 (2022): 110222.

[29] S. Zhang, S. Weinberg, M. DeBerge, et al., “Efferocytosis Fuels Requirements of Fatty Acid Oxidation and the Electron Transport Chain to Polarize Macrophages for Tissue Repair,” Cell Metabolism 29, no. 2 (2019): 443–456.

[30] S. Uderhardt, M. Herrmann, O. V. Oskolkova, et al., “12/15-Lipoxygenase Orchestrates the Clearance of Apoptotic Cells and Maintains Immunologic Tolerance,” Immunity 36, no. 5 (2012): 834–846.

[31] J. Dalli and C. N. Serhan, “Specific Lipid Mediator Signatures of Human Phagocytes: Microparticles Stimulate Macrophage Efferocytosis and Pro-Resolving Mediators,” Blood 120, no. 15 (2012): e60–e72.

[32] J. Dalli and C. Serhan, “Macrophage Proresolving Mediators – The When and Where,” Microbiology Spectrum 4, no. 3 (2016): 17–34.

[33] B. Cai, E. B. Thorp, A. C. Doran, et al., “MerTK Cleavage Limits Proresolving Mediator Biosynthesis and Exacerbates Tissue Inflammation,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 23 (2016): 6526–6531.

[34] N. Ag, S. J. Bensinger, C. Hong, et al., “Apoptotic Cells Promote Their Own Clearance and Immune Tolerance Through Activation of the Nuclear Receptor LXR,” Immunity 31, no. 2 (2009): 245–258.

[35] M. Schilperoort, D. Ngai, M. Katerelos, et al., “PFKFB2-Mediated Glycolysis Promotes Lactate-Driven Continual Efferocytosis by Macrophages,” Nature Metabolism 5, no. 3 (2023): 431–444.

[36] S. Morioka, J. S. A. Perry, M. H. Raymond, et al., “Efferocytosis Induces a Novel SLC Program to Promote Glucose Uptake and Lactate Release,” Nature 563, no. 7733 (2018): 714–718.

[37] D. He, Q. Mao, J. Jia, et al., “Pentose Phosphate Pathway Regulates Tolerogenic Apoptotic Cell Clearance and Immune Tolerance,” Frontiers in Immunology 12 (2021): 797091.

[38] B. D. Gerlach, P. B. Ampomah, and A. Yurdagul, “Efferocytosis Induces Macrophage Proliferation to Help Resolve Tissue Injury,” Cell Metabolism 33, no. 12 (2021): 2445–2463.

[39] M. Zhang, J. Wei, Y. Sun, et al., “The Efferocytosis Process in Aging: Supporting Evidence, Mechanisms, and Therapeutic Prospects for Age-Related Diseases,” Journal of Advanced Research 69 (2025): 31–49.

[40] R. P. H. De Maeyer and E. S. Chambers, “The Impact of Ageing on Monocytes and Macrophages,” Immunology Letters 230 (2021): 1–10.

[41] P. Liu, Q. Wang, S. Wang, et al., “Single-Cell RNA-Seq Reveals Aging-Related Impairment of Microglial Efferocytosis Contributing to Apoptotic Cells Accumulation After Retinal Injury,” Aging Cell 24, no. 8 (2025): e70097.

[42] C. V. Rothlin and S. Ghosh, “When Aging Gets on the Way of Disposal: Senescent Cell Suppression of Efferocytosis,” Journal of Cell Biology 222, no. 2 (2023): e202212023.

[43] M. Feng, W. Jiang, B. Y. S. Kim, et al., “Phagocytosis Checkpoints as New Targets for Cancer Immunotherapy,” Nature Reviews Cancer 19, no. 10 (2019): 568–586.

[44] D. Schloesser, L. Lindenthal, J. Sauer, et al., “Senescent Cells Suppress Macrophage-Mediated Corpse Removal via Upregulation of the CD47-QPCT/L Axis,” Journal of Cell Biology 222, no. 2 (2023): e202207097.

[45] D. M. Boucher, S. Robichaud, V. Lorant, et al., “Age-Related Impairments in Immune Cell Efferocytosis and Autophagy Hinder Atherosclerosis Regression,” Arteriosclerosis, Thrombosis, and Vascular Biology 45, no. 4 (2025): 481–495.

[46] E. F. Carrizales-Sepúlveda, A. Ordaz-Farías, R. Vera-Pineda, and R. Flores-Ramírez, “Periodontal Disease, Systemic Inflammation and the Risk of Cardiovascular Disease,” Heart, Lung & Circulation 27, no. 11 (2018): 1327–1334.

[47] R. Chen, H. Zhang, B. Tang, et al., “Macrophages in Cardiovascular Diseases: Molecular Mechanisms and Therapeutic Targets,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 130.

[48] T. V. Rohm, D. T. Meier, J. M. Olefsky, and M. Y. Donath, “Inflammation in Obesity, Diabetes, and Related Disorders,” Immunity 55, no. 1 (2022): 31–55.

[49] L. M. Coussens and Z. Werb, “Inflammation and Cancer,” Nature 420, no. 6917 (2002): 860–867.

[50] M. Bäck, A. Yurdagul, and I. Tabas, “Inflammation and Its Resolution in Atherosclerosis: Mediators and Therapeutic Opportunities,” Nature Reviews Cardiology 16, no. 7 (2019): 389–406.

[51] W. J. Yang, R. C. Cao, and W. Xiao, “Acinar ATP8b1/LPC Pathway Promotes Macrophage Efferocytosis and Clearance of Inflammation During Chronic Pancreatitis Development,” Cell Death & Disease 13, no. 10 (2022): 893.

[52] J. J. Lv, H. Wang, C. Zhang, et al., “CD147 Sparks Atherosclerosis by Driving M1 Phenotype and Impairing Efferocytosis,” Circulation Research 134, no. 2 (2024): 165–185.

[53] B. Li, Z. Xin, S. Gao, et al., “SIRT6-Regulated Macrophage Efferocytosis Epigenetically Controls Inflammation Resolution of Diabetic Periodontitis,” Theranostics 13, no. 1 (2023): 231–249.

[54] X. Wang, Q. He, C. Zhou, et al., “Prolonged Hypernutrition Impairs TREM2-Dependent Efferocytosis to License Chronic Liver Inflammation and NASH Development,” Immunity 56, no. 1 (2023): 11.

[55] J. Tang, Y. Jin, and F. Jia, “Gas6 Promotes Microglia Efferocytosis and Suppresses Inflammation Through Activating Axl/Rac1 Signaling in Subarachnoid Hemorrhage Mice,” Translational Stroke Research 14, no. 6 (2023): 955–969.

[56] S. Morioka, D. Kajioka, Y. Yamaoka, et al., “Chimeric Efferocytic Receptors Improve Apoptotic Cell Clearance and Alleviate Inflammation,” Cell 185, no. 26 (2022): 17.

[57] S. S. Adkar and N. J. Leeper, “Efferocytosis in Atherosclerosis,” Nature Reviews Cardiology 21, no. 11 (2024): 762–779.

[58] S. M. Aitcheson, F. D. Frentiu, S. E. Hurn, et al., “Skin Wound Healing: Normal Macrophage Function and Macrophage Dysfunction in Diabetic Wounds,” Molecules (Basel, Switzerland) 26, no. 16 (2021): 4917.

[59] D. Jia, S. Chen, P. Bai, et al., “Cardiac Resident Macrophage-Derived Legumain Improves Cardiac Repair by Promoting Clearance and Degradation of Apoptotic Cardiomyocytes After Myocardial Infarction,” Circulation 145, no. 20 (2022): 1542–1556.

[60] L. Zhou, Y. Lu, X. Qiu, et al., “Lipid Droplet Efferocytosis Attenuates Proinflammatory Signaling in Macrophages via TREM2- and MS4A7-Dependent Mechanisms,” Cell Reports 44, no. 2 (2025): 115310.

[61] J. Xing, K. Wang, Y. C. Xu, et al., “Efferocytosis: Unveiling Its Potential in Autoimmune Disease and Treatment Strategies,” Autoimmunity Reviews 23, no. 6 (2024): 103578.

[62] L. E. Muñoz, K. Lauber, M. Schiller, et al., “The Role of Defective Clearance of Apoptotic Cells in Systemic Autoimmunity,” Nature Reviews Rheumatology 6, no. 5 (2010): 280–289.

[63] Z. G. Ramirez-Ortiz, W. F. Pendergraft, A. Prasad, et al., “The Scavenger Receptor SCARF1 Mediates the Clearance of Apoptotic Cells and Prevents Autoimmunity,” Nature Immunology 14, no. 9 (2013): 917–926.

[64] R. Hanayama, M. Tanaka, K. Miyasaka, et al., “Autoimmune Disease and Impaired Uptake of Apoptotic Cells in MFG-E8-Deficient Mice,” Science 304, no. 5674 (2004): 1147–1150.

[65] S. Nagata, “Apoptosis and Clearance of Apoptotic Cells,” Annual Review of Immunology 36 (2018): 489–517.

[66] C. E. J. Waterborg, M. I. Koenders, P. van Lent, et al., “Tyro3/Axl/Mertk-Deficient Mice Develop Bone Marrow Edema Which Is an Early Pathological Marker in Rheumatoid Arthritis,” PLoS ONE 13, no. 10 (2018): e0205902.

[67] M. Lee, M. K. Kim, S. Mo, et al., “Inhibition of Salt-Inducible Kinases Resolves Autoimmune Arthritis by Promoting Macrophage Efferocytosis,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 293.

[68] H. Qiu, Z. Shao, X. Wen, et al., “Efferocytosis: An Accomplice of Cancer Immune Escape,” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 167 (2023): 115540.

[69] P. Aehnlich, R. M. Powell, M. J. W. Peeters, et al., “TAM Receptor Inhibition-Implications for Cancer and the Immune System,” Cancers 13, no. 6 (2021): 1195.

[70] K. K. Kim, M. R. Dotson, M. Agarwal, et al., “Efferocytosis of Apoptotic Alveolar Epithelial Cells Is Sufficient to Initiate Lung Fibrosis,” Cell Death & Disease 9, no. 11 (2018): 1056.

[71] B. Jäger, B. Seeliger, O. Terwolbeck, et al., “The NLRP3-Inflammasome-Caspase-1 Pathway Is Upregulated in Idiopathic Pulmonary Fibrosis and Acute Exacerbations and Is Inducible by Apoptotic A549 Cells,” Frontiers in Immunology 12 (2021): 642855.

[72] D. Guan, P. Huang, X. Liu, et al., “Deficiency of Myeloid NPC1 Exacerbates Liver Injury and Fibrosis by Impairing Macrophage Efferocytosis,” Journal of Advanced Research 72 (2025): 213–227.

[73] Y. She, X. Xu, Q. Yu, et al., “Elevated Expression of Macrophage MERTK Exhibits Profibrotic Effects and Results in Defective Regulation of Efferocytosis Function in Pulmonary Fibrosis,” Respiratory Research 24, no. 1 (2023): 118.

[74] P. An, L. L. Wei, S. Zhao, et al., “Hepatocyte Mitochondria-Derived Danger Signals Directly Activate Hepatic Stellate Cells and Drive Progression of Liver Fibrosis,” Nature Communications 11, no. 1 (2020): 2362.

[75] T. S. Rigoni, N. S. Vellozo, K. Guimarães-Pinto, et al., “Axl Receptor Induces Efferocytosis, Dampens M1 Macrophage Responses and Promotes Heart Pathology in Trypanosoma cruzi Infection,” Communications Biology 5, no. 1 (2022): 1421.

[76] D. Ma, Y. Hua, and Y. Lu, “Complement Factor H Drives Idiopathic Pulmonary Fibrosis by Autocrine C3 Regulation, Suppressing Macrophage Phagocytosis and Enhancing Fibrotic Progression,” Biochemical and Biophysical Research Communications 745 (2025): 151220.

[77] Z. Wang, X. Chen, J. Li, et al., “Macrophages Atp6v0d2 Regulates XBP1-Mediated Cholesterol Metabolism to Suppress Metabolic Dysfunction-Associated Steatohepatitis Progression,” International Immunopharmacology 161 (2025): 115088.

[78] Y. Wang, J. Wang, J. Zhang, et al., “Stiffness Sensing via Piezo1 Enhances Macrophage Efferocytosis and Promotes the Resolution of Liver Fibrosis,” Science Advances 10, no. 23 (2024): eadj3289.

[79] Y. Zhang, Y. Wang, J. Ding, and P. Liu, “Efferocytosis in Multisystem Diseases (Review),” Molecular Medicine Reports 25, no. 1 (2022): 13.

[80] A. A. Baxter, I. K. H. Poon, and D. Karunakaran, “Macrophage Cannibalism: Efferocytosis in Atherosclerosis,” Current Opinion in Lipidology 36, no. 6 (2025): 333–341.

[81] D. Kumar, R. Pandit, and A. Yurdagul, “Mechanisms of Continual Efferocytosis by Macrophages and Its Role in Mitigating Atherosclerosis,” Immunometabolism 5, no. 1 (2023): e00017.

[82] Y. Su, H. Wang, H. Liu, and Y. Tang, “Macrophage Efferocytosis: Mechanisms and Therapeutic Opportunities for Future Cardiovascular Diseases,” International Immunopharmacology 168, no. pt 2 (2025): 115899.

[83] K. Shkarina, E. Hasel de Carvalho, J. C. Santos, et al., “Optogenetic Activators of Apoptosis, Necroptosis, and Pyroptosis,” Journal of Cell Biology 221, no. 6 (2022): e202109038.

[84] J. Lu, W. Shi, B. Liang, et al., “Efficient Engulfment of Necroptotic and Pyroptotic Cells by Nonprofessional and Professional Phagocytes,” Cell Discovery 5 (2019): 39.

[85] Y. Kojima, J. P. Volkmer, K. McKenna, et al., “CD47-Blocking Antibodies Restore Phagocytosis and Prevent Atherosclerosis,” Nature 536, no. 7614 (2016): 86–90.

[86] B. Singla, R. V. Aithbathula, N. Pervaiz, et al., “CD47 Activation by Thrombospondin-1 in Lymphatic Endothelial Cells Suppresses Lymphangiogenesis and Promotes Atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology 43, no. 7 (2023): 1234–1250.

[87] X. Hu, Y. Nan, Y. Zhang, et al., “Simultaneously Blocking ANGPTL3 and CD47 Prevents the Progression of Atherosclerosis Through Regulating Lipid Metabolism, Macrophagic Efferocytosis and Lipid Peroxidation,” Pharmacological Research 210 (2024): 107486.

[88] P. Doddapattar, R. Dev, M. Ghatge, et al., “Myeloid Cell PKM2 Deletion Enhances Efferocytosis and Reduces Atherosclerosis,” Circulation Research 130, no. 9 (2022): 1289–1305.

[89] M. G. Kiss, N. Papac-Miličević, F. Porsch, et al., “Cell-Autonomous Regulation of Complement C3 by Factor H Limits Macrophage Efferocytosis and Exacerbates Atherosclerosis,” Immunity 56, no. 8 (2023): 10.

[90] P. L. Shook, M. Singh, and K. Singh, “Macrophages in the Inflammatory Phase Following Myocardial Infarction: Role of Exogenous Ubiquitin,” Biology 12, no. 9 (2023): 1258.

[91] M. DeBerge, S. Zhang, K. Glinton, et al., “Efferocytosis and Outside-In Signaling by Cardiac Phagocytes. Links to Repair, Cellular Programming, and Intercellular Crosstalk in Heart,” Frontiers in Immunology 8 (2017): 1428.

[92] K. E. Glinton, W. Ma, C. Lantz, et al., “Macrophage-Produced VEGFC Is Induced by Efferocytosis to Ameliorate Cardiac Injury and Inflammation,” Journal of Clinical Investigation 132, no. 9 (2022): e140685.

[93] S. Gong, M. Zhai, J. Shi, et al., “TREM2 Macrophage Promotes Cardiac Repair in Myocardial Infarction by Reprogramming Metabolism via SLC25A53,” Cell Death and Differentiation 31, no. 2 (2024): 239–253.

[94] S. Cai, M. Zhao, B. Zhou, et al., “Mitochondrial Dysfunction in Macrophages Promotes Inflammation and Suppresses Repair After Myocardial Infarction,” Journal of Clinical Investigation 133, no. 4 (2023): e159498.

[95] M. Kiriakidou and C. L. Ching, “Systemic Lupus Erythematosus,” Annals of Internal Medicine 172, no. 11 (2020): ITC81–ITC96.

[96] X. Cao, F. Li, X. Xie, et al., “Efferocytosis and Inflammation: A Bibliometric and Systematic Analysis,” Frontiers in Medicine 12 (2025): 1498503.

[97] X. Tang, Y. Peng, Z. Jiang, et al., “Efferocytosis and Its Role in Rheumatic Diseases,” Arthritis & Rheumatology 77, no. 12 (2025): 1635–1650.

[98] M. Wigren, J. Nilsson, and M. J. Kaplan, “Pathogenic Immunity in Systemic Lupus Erythematosus and Atherosclerosis: Common Mechanisms and Possible Targets for Intervention,” Journal of Internal Medicine 278, no. 5 (2015): 494–506.

[99] E. J. Yoo, K. H. Oh, H. Piao, et al., “Macrophage Transcription Factor TonEBP Promotes Systemic Lupus Erythematosus and Kidney Injury via Damage-Induced Signaling Pathways,” Kidney International 104, no. 1 (2023): 163–180.

[100] L. Geng, J. Zhao, Y. Deng, et al., “Human SLE Variant NCF1-R90H Promotes Kidney Damage and Murine Lupus Through Enhanced Tfh2 Responses Induced by Defective Efferocytosis of Macrophages,” Annals of the Rheumatic Diseases 81, no. 2 (2022): 255–267.

[101] M. N. Manoussakis, G. E. Fragoulis, A. G. Vakrakou, and H. M. Moutsopoulos, “Impaired Clearance of Early Apoptotic Cells Mediated by Inhibitory IgG Antibodies in Patients With Primary Sjögren's Syndrome,” PLoS ONE 9, no. 11 (2014): e112100.

[102] R. M. Clancy, P. J. Neufing, P. Zheng, et al., “Impaired Clearance of Apoptotic Cardiocytes Is Linked to Anti-SSA/Ro and -SSB/La Antibodies in the Pathogenesis of Congenital Heart Block,” Journal of Clinical Investigation 116, no. 9 (2006): 2413–2422.

[103] R. Witas, A. Rasmussen, R. H. Scofield, et al., “Defective Efferocytosis in a Murine Model of Sjögren's Syndrome Is Mediated by Dysfunctional Mer Tyrosine Kinase Receptor,” International Journal of Molecular Sciences 22, no. 18 (2021): 9711.

[104] R. Witas, Y. Shen, and C. Q. Nguyen, “Bone Marrow-Derived Macrophages From a Murine Model of Sjögren's Syndrome Demonstrate an Aberrant, Inflammatory Response to Apoptotic Cells,” Scientific Reports 12, no. 1 (2022): 8593.

[105] S. Alivernini, L. MacDonald, A. Elmesmari, et al., “Distinct Synovial Tissue Macrophage Subsets Regulate Inflammation and Remission in Rheumatoid Arthritis,” Nature Medicine 26, no. 8 (2020): 1295–1306.

[106] C. E. J. Waterborg, S. Beermann, M. G. A. Broeren, et al., “Protective Role of the MER Tyrosine Kinase via Efferocytosis in Rheumatoid Arthritis Models,” Frontiers in Immunology 9 (2018): 742.

[107] C. E. J. Waterborg and M. G. A. Broeren, “The Level of Synovial AXL Expression Determines the Outcome of Inflammatory Arthritis, Possibly Depending on the Upstream Role of TGF-β1,” Rheumatology 58, no. 3 (2019): 536–546.

[108] F. D. Shi and V. W. Yong, “Neuroinflammation Across Neurological Diseases,” Science 388, no. 6753 (2025): eadx0043.

[109] W. Zhang, D. Xiao, Q. Mao, and H. Xia, “Role of Neuroinflammation in Neurodegeneration Development,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 267.

[110] T. Bartels, S. De Schepper, and S. Hong, “Microglia Modulate Neurodegeneration in Alzheimer's and Parkinson's Diseases,” Science 370, no. 6512 (2020): 66–69.

[111] J. Zhao, W. Zhang, T. Wu, et al., “Efferocytosis in the Central Nervous System,” Frontiers in Cell and Developmental Biology 9 (2021): 773344.

[112] D. A. Nie, J. Yu, W. Huang, et al., “The Role of Microglia in Neurodegenerative Diseases,” Molecular Immunology 185 (2025): 127–135.

[113] Y. Chen, Y. Kou, Y. Ni, et al., “Microglia Efferocytosis: An Emerging Mechanism for the Resolution of Neuroinflammation in Alzheimer's Disease,” Journal of Neuroinflammation 22, no. 1 (2025): 96.

[114] S. Wang, M. Mustafa, C. M. Yuede, et al., “Anti-Human TREM2 Induces Microglia Proliferation and Reduces Pathology in an Alzheimer's Disease Model,” Journal of Experimental Medicine 217, no. 9 (2020): e20200785.

[115] O. Butovsky and H. L. Weiner, “Microglial Signatures and Their Role in Health and Disease,” Nature Reviews Neuroscience 19, no. 10 (2018): 622–635.

[116] C. Romero-Molina, F. Garretti, S. J. Andrews, et al., “Microglial Efferocytosis: Diving Into the Alzheimer's Disease Gene Pool,” Neuron 110, no. 21 (2022): 3513–3533.

[117] S. Yang, Y. Du, Y. Li, et al., “Tyrosine Phosphorylation and Palmitoylation of TRPV2 Ion Channel Tune Microglial Beta-Amyloid Peptide Phagocytosis,” Journal of Neuroinflammation 21, no. 1 (2024): 218.

[118] S. J. Andrews, A. E. Renton, B. Fulton-Howard, et al., “The Complex Genetic Architecture of Alzheimer's Disease: Novel Insights and Future Directions,” EBioMedicine 90 (2023): 104511.

[119] W. Wang, Y. Wang, F. Wang, et al., “Gastrodin Regulates the TLR4/TRAF6/NF-κB Pathway to Reduce Neuroinflammation and Microglial Activation in an AD Model,” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 128 (2024): 155518.

[120] D. He, H. Xu, H. Zhang, et al., “Disruption of the IL-33-ST2-AKT Signaling Axis Impairs Neurodevelopment by Inhibiting Microglial Metabolic Adaptation and Phagocytic Function,” Immunity 55, no. 1 (2022): 9.

[121] L. Li, W. Jiang, B. Yu, et al., “Quercetin Improves Cerebral Ischemia/Reperfusion Injury by Promoting Microglia/Macrophages M2 Polarization via Regulating PI3K/Akt/NF-κB Signaling Pathway,” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 168 (2023): 115653.

[122] C. Kim, D. H. Ho, J. E. Suk, et al., “Neuron-Released Oligomeric α-Synuclein Is an Endogenous Agonist of TLR2 for Paracrine Activation of Microglia,” Nature Communications 4 (2013): 1562.

[123] H. Long, S. Zhang, S. Zeng, et al., “Interaction of RAGE With α-Synuclein Fibrils Mediates Inflammatory Response of Microglia,” Cell Reports 40, no. 12 (2022): 111401.

[124] Y. R. Choi, S. J. Kang, J. M. Kim, et al., “FcγRIIB Mediates the Inhibitory Effect of Aggregated α-Synuclein on Microglial Phagocytosis,” Neurobiology of Disease 83 (2015): 90–99.

[125] N. Panicker, S. Sarkar, D. S. Harischandra, et al., “Fyn Kinase Regulates Misfolded α-Synuclein Uptake and NLRP3 Inflammasome Activation in Microglia,” Journal of Experimental Medicine 216, no. 6 (2019): 1411–1430.

[126] X. D. Xie, S. S. Dong, R. J. Liu, et al., “Mechanism of Efferocytosis in Determining Ischaemic Stroke Resolution-Diving Into Microglia/Macrophage Functions and Therapeutic Modality,” Molecular Neurobiology 61, no. 10 (2024): 7583–7602.

[127] C. A. Morris, M. A. Sadek, P. Modi, et al., “The Role of Efferocytosis in Ischemic Stroke and Insights From Retinopathy,” Trends in Neurosciences 48, no. 8 (2025): 624–639.

[128] L. Peng, G. Hu, Q. Yao, et al., “Microglia Autophagy in Ischemic Stroke: A Double-Edged Sword,” Frontiers in Immunology 13 (2022): 1013311.

[129] C. Nakahashi-Oda, S. Fujiyama, Y. Nakazawa, et al., “CD300a Blockade Enhances Efferocytosis by Infiltrating Myeloid Cells and Ameliorates Neuronal Deficit After Ischemic Stroke,” Science Immunology 6, no. 64 (2021): eabe7915.

[130] W. Cai, X. Dai, J. Chen, et al., “STAT6/Arg1 Promotes Microglia/Macrophage Efferocytosis and Inflammation Resolution in Stroke Mice,” JCI Insight 4, no. 20 (2019): e131355.

[131] S. Razi and F. Kargarijam, “Macrophage Efferocytosis in Health and Disease,” Cell Biochemistry and Function 41, no. 2 (2023): 152–165.

[132] S. Zhang, Y. Jiang, L. Shi, et al., “Identification and Analysis of Key Genes Related to Efferocytosis in Colorectal Cancer,” BMC Medical Genomics 17, no. 1 (2024): 198.

[133] W. Yu, D. Yao, X. Ma, et al., “A Novel Efferocytosis-Related Gene Signature for Predicting Prognosis and Therapeutic Response in Bladder Cancer,” Scientific Reports 15, no. 1 (2025): 19912.

[134] Y. Xie, H. Chen, X. Zhang, et al., “Integration of the Bulk Transcriptome and Single-Cell Transcriptome Reveals Efferocytosis Features in Lung Adenocarcinoma Prognosis and Immunotherapy by Combining Deep Learning,” Cancer Cell International 24, no. 1 (2024): 388.

[135] L. Wang, J. Ge, Z. Wang, et al., “A Signature Based on Efferocytosis-Related Genes for the Evaluation of Prognosis and the Tumour Microenvironment in Gastric Cancer,” Scientific Reports 15, no. 1 (2025): 14226.

[136] T. Kimura, S. Nada, N. Takegahara, et al., “Polarization of M2 Macrophages Requires Lamtor1 That Integrates Cytokine and Amino-Acid Signals,” Nature Communications 7 (2016): 13130.

[137] L. Zhou and G. K. Matsushima, “Tyro3, Axl, Mertk Receptor-Mediated Efferocytosis and Immune Regulation in the Tumor Environment,” International Review of Cell and Molecular Biology 361 (2021): 165–210.

[138] M. A. Bouhlel, B. Derudas, E. Rigamonti, et al., “PPARgamma Activation Primes Human Monocytes Into Alternative M2 Macrophages With Anti-Inflammatory Properties,” Cell Metabolism 6, no. 2 (2007): 137–143.

[139] M. Ghahremani Piraghaj, S. Soudi, and H. Ghanbarian, “Effect of Efferocytosis of Apoptotic Mesenchymal Stem Cells (MSCs) on C57BL/6 Peritoneal Macrophages Function,” Life Sciences 212 (2018): 203–212.

[140] R. E. Menjivar, Z. C. Nwosu, W. Du, et al., “Arginase 1 Is a Key Driver of Immune Suppression in Pancreatic Cancer,” Elife 12 (2023): e80721.

[141] Y. Astuti, M. Raymant, V. Quaranta, et al., “Efferocytosis Reprograms the Tumor Microenvironment to Promote Pancreatic Cancer Liver Metastasis,” Nature Cancer 5, no. 5 (2024): 774–790.

[142] L. Zhao, A. D. Giannou, Y. Xu, et al., “Efferocytosis Fuels Malignant Pleural Effusion Through TIMP1,” Science Advances 7, no. 33 (2021): eabd6734.

[143] C. Lang, S. Roy, Y. Wang, et al., “Efferocytosis Drives Myeloid NLRP3 Dependent Inflammasome Signaling Secretion of IL-1β to Promote Tumor Growth,” Frontiers in Immunology 13 (2022): 993771.

[144] C. Ramos and R. Oehler, “Clearance of Apoptotic Cells by Neutrophils in Inflammation and Cancer,” Cell Death Discovery 10, no. 1 (2024): 26.

[145] S. Jaillon, A. Ponzetta, D. Di Mitri, et al., “Neutrophil Diversity and Plasticity in Tumour Progression and Therapy,” Nature Reviews Cancer 20, no. 9 (2020): 485–503.

[146] P. C. Rodriguez, D. G. Quiceno, J. Zabaleta, et al., “Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses,” Cancer Research 64, no. 16 (2004): 5839–5849.

[147] B. M. Szczerba, F. Castro-Giner, M. Vetter, et al., “Neutrophils Escort Circulating Tumour Cells to Enable Cell Cycle Progression,” Nature 566, no. 7745 (2019): 553–557.

[148] F. Tzelepis, M. Verway, J. Daoud, et al., “Annexin1 Regulates DC Efferocytosis and Cross-Presentation During Mycobacterium Tuberculosis Infection,” Journal of Clinical Investigation 125, no. 2 (2015): 752–768.

[149] M. Kool, G. van Loo, W. Waelput, et al., “The Ubiquitin-Editing Protein A20 Prevents Dendritic Cell Activation, Recognition of Apoptotic Cells, and Systemic Autoimmunity,” Immunity 35, no. 1 (2011): 82–96.

[150] U. Trahtemberg and D. Mevorach, “Apoptotic Cells Induced Signaling for Immune Homeostasis in Macrophages and Dendritic Cells,” Frontiers in Immunology 8 (2017): 1356.

[151] Y. Ma, T. Jiang, X. Zhu, et al., “Efferocytosis in Dendritic Cells: An Overlooked Immunoregulatory Process,” Frontiers in Immunology 15 (2024): 1415573.

[152] A. A. Barkal, R. E. Brewer, M. Markovic, et al., “CD24 Signalling Through Macrophage Siglec-10 Is a Target for Cancer Immunotherapy,” Nature 572, no. 7769 (2019): 392–396.

[153] A. Gruenwald, M. Neururer, S. Eidenhammer, et al., “The cGAS-STING Pathway Drives Inflammation in Usual Interstitial Pneumonia, Phagocytosis Could Prevent Inflammation but Is Inhibited by the Don't Eat Me Signal CD47,” Pathology, Research and Practice 260 (2024): 155432.

[154] G. Li, J. Xu, X. Tian, et al., “Efferocytosis: The Art of Cellular Clearance and Novel Perspectives in Disease Therapy,” Molecular Cancer 24, no. 1 (2025): 268.

[155] M. Gray, K. Miles, D. Salter, et al., “Apoptotic Cells Protect Mice From Autoimmune Inflammation by the Induction of Regulatory B Cells,” Proceedings of the National Academy of Sciences of the United States of America 104, no. 35 (2007): 14080–14085.

[156] F. Bonnefoy, A. Daoui, S. Valmary-Degano, et al., “Apoptotic Cell Infusion Treats Ongoing Collagen-Induced Arthritis, Even in the Presence of Methotrexate, and Is Synergic With Anti-TNF Therapy,” Arthritis Research & Therapy 18, no. 1 (2016): 184.

[157] X. Tang, Y. Peng, Z. Jiang, et al., “Efferocytosis and Its Role in Rheumatic Diseases,” Arthritis & Rheumatology 77, no. 12 (2025): 1635–1650.

[158] E. Toussirot, F. Bonnefoy, C. Vauchy, et al., “Mini-Review: The Administration of Apoptotic Cells for Treating Rheumatoid Arthritis: Current Knowledge and Clinical Perspectives,” Frontiers in Immunology 12 (2021): 630170.

[159] M. B. Naeini, A. A. Momtazi-Borojeni, S. Ganjali, et al., “Phosphatidylserine-Containing Liposomes: Therapeutic Potentials Against Hypercholesterolemia and Atherosclerosis,” European Journal of Pharmacology 908 (2021): 174308.

[160] J. Ji, S. Yang, Y. Xu, et al., “M2-ApoBDs as a Therapeutic Strategy for Systemic Lupus Erythematosus: Targeted Macrophage Reprogramming and Treg Differentiation,” Journal of Nanobiotechnology 23, no. 1 (2025): 354.

[161] Y. Zhang, J. Ding, Y. Wang, et al., “Guanxinkang Decoction Attenuates the Inflammation in Atherosclerosis by Regulating Efferocytosis and MAPKs Signaling Pathway in LDLR(-/-) Mice and RAW264.7 Cells,” Frontiers in Pharmacology 12 (2021): 731769.

[162] S. Y. Liu, Y. J. Yeh, T. Y. Xue, et al., “Hydroxychloroquine Enhances Efferocytosis and Modulates Inflammation via MerTK/Gas6 Signaling in a Pristane-Induced Lupus Mouse Model,” Frontiers in Immunology 16 (2025): 1524315.

[163] B. T. van den Brand, S. Abdollahi-Roodsaz, E. A. Vermeij, et al., “Therapeutic Efficacy of Tyro3, Axl, and Mer Tyrosine Kinase Agonists in Collagen-Induced Arthritis,” Arthritis and Rheumatism 65, no. 3 (2013): 671–680.

[164] K. Lauber, H. Keppeler, L. E. Munoz, et al., “Milk Fat Globule-EGF Factor 8 Mediates the Enhancement of Apoptotic Cell Clearance by Glucocorticoids,” Cell Death and Differentiation 20, no. 9 (2013): 1230–1240.

[165] A. McColl, S. Bournazos, S. Franz, et al., “Glucocorticoids Induce Protein S-Dependent Phagocytosis of Apoptotic Neutrophils by Human Macrophages,” Journal of Immunology 183, no. 3 (1950): 2167–2175.

[166] R. P. H. De Maeyer, R. C. van de Merwe, R. Louie, et al., “Blocking Elevated p38 MAPK Restores Efferocytosis and Inflammatory Resolution in the Elderly,” Nature Immunology 21, no. 6 (2020): 615–625.

[167] J. W. Harder, J. Ma, P. Alard, et al., “Male Microbiota-Associated Metabolite Restores Macrophage Efferocytosis in Female Lupus-Prone Mice via Activation of PPARγ/LXR Signaling Pathways,” Journal of Leukocyte Biology 113, no. 1 (2023): 41–57.

[168] J. K. Park, Y. J. Lee, J. S. Park, et al., “CD47 Potentiates Inflammatory Response in Systemic Lupus Erythematosus,” Cells 10, no. 5 (2021): 1151.

[169] W. A. Julliard, Y. P. A. Myo, A. Perelas, et al., “Specialized Pro-Resolving Mediators as Modulators of Immune Responses,” Seminars in Immunology 59 (2022): 101605.

[170] M. G. Duvall, T. R. Bruggemann, and B. D. Levy, “Bronchoprotective Mechanisms for Specialized Pro-Resolving Mediators in the Resolution of Lung Inflammation,” Molecular Aspects of Medicine 58 (2017): 44–56.

[171] E. R. Ağış, B. Savaş, and M. Melli, “Impact of Colonic Mucosal Lipoxin A4 Synthesis Capacity on Healing in Rats With Dextran Sodium Sulfate-Induced Colitis,” Prostaglandins & Other Lipid Mediators 121 (2015): 63–69.

[172] M. Vomero, L. Lamberti, E. Corberi, et al., “Specialized Pro-Resolving Mediators and Autoimmunity: Recent Insights and Future Perspectives,” Autoimmunity Reviews 24, no. 11 (2025): 103896.

[173] S. Yuan, Y. Chai, J. Xu, et al., “Engineering Efferocytosis-Mimicking Nanovesicles to Regulate Joint Anti-Inflammation and Peripheral Immunosuppression for Rheumatoid Arthritis Therapy,” Advanced Science 11, no. 28 (2024): e2404198.

[174] H. Tan, W. Li, Z. Pang, et al., “Genetically Engineered Macrophages Co-Loaded With CD47 Inhibitors Synergistically Reconstruct Efferocytosis and Improve Cardiac Remodeling Post Myocardial Ischemia Reperfusion Injury,” Advanced Healthcare Materials 13, no. 16 (2024): e2303267.

[175] Y. Y. Gao, T. Tao, D. Wu, et al., “MFG-E8 Attenuates Inflammation in Subarachnoid Hemorrhage by Driving Microglial M2 Polarization,” Experimental Neurology 336 (2021): 113532.

[176] L. S. Tong, A. W. Shao, Y. B. Ou, et al., “Recombinant Gas6 Augments Axl and Facilitates Immune Restoration in an Intracerebral Hemorrhage Mouse Model,” Journal of Cerebral Blood Flow and Metabolism 37, no. 6 (2017): 1971–1981.

[177] C. A. Traughber, K. Timinski, A. Prince, et al., “Disulfiram Reduces Atherosclerosis and Enhances Efferocytosis, Autophagy, and Atheroprotective Gut Microbiota in Hyperlipidemic Mice,” Journal of the American Heart Association 13, no. 8 (2024): e033881.

[178] T. Kiyota, J. Machhi, Y. Lu, et al., “URMC-099 Facilitates Amyloid-β Clearance in a Murine Model of Alzheimer's Disease,” Journal of Neuroinflammation 15, no. 1 (2018): 137.

[179] C. K. Gavini, N. Elshareif, G. Aubert, et al., “LXR Agonist Improves Peripheral Neuropathy and Modifies PNS Immune Cells in Aged Mice,” Journal of Neuroinflammation 19, no. 1 (2022): 57.

[180] P. DeRose, P. E. Thorpe, and D. E. Gerber, “Development of Bavituximab, a Vascular Targeting Agent With Immune-Modulating Properties, for Lung Cancer Treatment,” Immunotherapy 3, no. 8 (2011): 933–944.

[181] K. I. Ly, L. G. Richardson, M. Liu, et al., “Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients,” Clinical Cancer Research 29, no. 16 (2023): 3017–3025.

[182] P. Chalasani, M. Marron, D. Roe, et al., “A Phase I Clinical Trial of Bavituximab and Paclitaxel in Patients With HER2 Negative Metastatic Breast Cancer,” Cancer Medicine 4, no. 7 (2015): 1051–1059.

[183] J. E. Grilley-Olson, J. Weiss, A. Ivanova, et al., “Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer,” Clinical Lung Cancer 19, no. 4 (2018): e481.

[184] J. Meyer, Y. Arriaga, J. Anandam, et al., “A Phase I Clinical Trial of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma,” American Journal of Clinical Oncology 41, no. 10 (2018): 972–976.

[185] Y. R. Miao, E. B. Rankin, and A. J. Giaccia, “Therapeutic Targeting of the Functionally Elusive TAM Receptor Family,” Nature Reviews Drug Discovery 23, no. 3 (2024): 201–217.

[186] S. Peters, L. Paz-Ares, R. S. Herbst, and M. Reck, “Addressing CPI Resistance in NSCLC: Targeting TAM Receptors to Modulate the Tumor Microenvironment and Future Prospects,” Journal for Immunotherapy of Cancer 10, no. 7 (2022): e004863.

[187] K. C. Lahey, V. Gadiyar, A. Hill, et al., “Mertk: An Emerging Target in Cancer Biology and Immuno-Oncology,” International Review of Cell and Molecular Biology 368 (2022): 35–59.

[188] L. Kong, X. Lu, X. Chen, et al., “Qigesan Inhibits Esophageal Cancer Cell Invasion and Migration by Inhibiting Gas6/Axl-Induced Epithelial-Mesenchymal Transition,” Aging 12, no. 10 (2020): 9714–9725.

[189] H. Sadahiro, K. D. Kang, J. T. Gibson, et al., “Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma,” Cancer Research 78, no. 11 (2018): 3002–3013.

[190] M. Tanaka and D. W. Siemann, “Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer,” International Journal of Molecular Sciences 22, no. 18 (2021): 9953.

[191] N. Okura, N. Nishioka, T. Yamada, et al., “ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer,” Clinical Cancer Research 26, no. 9 (2020): 2244–2256.

[192] R. Nakamura, T. Yamada, S. Tokuda, et al., “Triple Combination Therapy Comprising Osimertinib, an AXL Inhibitor, and an FGFR Inhibitor Improves the Efficacy of EGFR-Mutated Non-Small Cell Lung Cancer,” Cancer Letters 598 (2024): 217124.

[193] Z. Jiang, S. O. Lim, M. Yan, et al., “TYRO3 Induces Anti-PD-1/PD-L1 Therapy Resistance by Limiting Innate Immunity and Tumoral Ferroptosis,” Journal of Clinical Investigation 131, no. 8 (2021): e139434.

[194] P. M. D'Cruz, D. Yasumura, and J. Weir, “Mutation of the Receptor Tyrosine Kinase Gene Mertk in the Retinal Dystrophic RCS Rat,” Human Molecular Genetics 9, no. 4 (2000): 645–651.

[195] Y. T. Akalu, M. E. Mercau, M. Ansems, et al., “Tissue-Specific Modifier Alleles Determine Mertk Loss-of-Function Traits,” Elife 11 (2022): e80530.

[196] K. X. Song, J. X. Wang, and D. Huang, “Therapy-Induced Senescent Tumor Cells in Cancer Relapse,” Journal of the National Cancer Center 3, no. 4 (2023): 273–278.

[197] A. Biedermann, M. Patra-Kneuer, D. Mougiakakos, et al., “Blockade of the CD47/SIRPα Checkpoint Axis Potentiates the Macrophage-Mediated Antitumor Efficacy of Tafasitamab,” Haematologica 109, no. 12 (2024): 3928–3940.

[198] W. B. Yu, Z. H. Ye, J. J. Shi, et al., “Dual Blockade of GSTK1 and CD47 Improves Macrophage-Mediated Phagocytosis on Cancer Cells,” Biochemical Pharmacology 236 (2025): 116898.

[199] S. M. Steggerda, M. K. Bennett, J. Chen, et al., “Inhibition of Arginase by CB-1158 Blocks Myeloid Cell-Mediated Immune Suppression in the Tumor Microenvironment,” Journal for Immunotherapy of Cancer 5, no. 1 (2017): 101.

[200] M. M. Grzybowski, P. S. Stańczak, P. Pomper, et al., “OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer,” Cancers 14, no. 16 (2022): 3967.

[201] P. Pilanc, K. Wojnicki, A. J. Roura, et al., “A Novel Oral Arginase 1/2 Inhibitor Enhances the Antitumor Effect of PD-1 Inhibition in Murine Experimental Gliomas by Altering the Immunosuppressive Environment,” Frontiers in Oncology 11 (2021): 703465.

[202] M. Aaboe Jørgensen, S. Ugel, and M. Linder Hübbe, “Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize With Anti-PD-1 Checkpoint Blockade,” Cancer Immunology Research 9, no. 11 (2021): 1316–1326.

[203] C. L. Lorentzen, E. Martinenaite, J. W. Kjeldsen, et al., “Arginase-1 Targeting Peptide Vaccine in Patients With Metastatic Solid Tumors—A Phase I Trial,” Frontiers in Immunology 13 (2022): 1023023.

[204] J. Miska, A. Rashidi, C. Lee-Chang, et al., “Polyamines Drive Myeloid Cell Survival by Buffering Intracellular pH to Promote Immunosuppression in Glioblastoma,” Science Advances 7, no. 8 (2021): eabc8929.

[205] M. Colonna, “The Biology of TREM Receptors,” Nature Reviews Immunology 23, no. 9 (2023): 580–594.

[206] O. O. Yeku, M. Barve, W. W. Tan, et al., “Myeloid Targeting Antibodies PY159 and PY314 for Platinum-Resistant Ovarian Cancer,” Journal for Immunotherapy of Cancer 13, no. 3 (2025): e010959.

[207] K. E. Beckermann, A. Patnaik, I. Winer, et al., “A Phase 1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of py314 in Combination With Pembrolizumab in Patients With Advanced Renal Cell Carcinoma,” Investigational New Drugs 42, no. 2 (2024): 179–184.

[208] Y. Liu, R. Niu, X. Zhang, et al., “Metal-Organic Framework-Based Nanovaccine for Relieving Immunosuppressive Tumors via Hindering Efferocytosis of Macrophages and Promoting Pyroptosis and Cuproptosis of Cancer Cells,” ACS Nano 18, no. 19 (2024): 12386–12400.

[209] X. Zhou, D. Li, S. Xia, et al., “RNA-Based Modulation of Macrophage-Mediated Efferocytosis Potentiates Antitumor Immunity in Colorectal Cancer,” Journal of Controlled Release 366 (2024): 128–141.

[210] D. Hsiehchen, M. S. Beg, R. Kainthla, et al., “The Phosphatidylserine Targeting Antibody Bavituximab Plus Pembrolizumab in Unresectable Hepatocellular Carcinoma: A Phase 2 Trial,” Nature Communications 15, no. 1 (2024): 2178.

[211] D. E. Gerber, L. Horn, M. Boyer, et al., “Randomized Phase III Study of Docetaxel Plus Bavituximab in Previously Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer,” Annals of Oncology 29, no. 7 (2018): 1548–1553.

[212] Y. Y. Chen, C. F. Lo, T. Y. Chiu, et al., “BPRDP056, a Novel Small Molecule Drug Conjugate Specifically Targeting Phosphatidylserine for Cancer Therapy,” Translational Oncology 14, no. 1 (2021): 100897.

[213] J. Li, Y. Bai, Z. Chen, et al., “SAFFRON-104: A Phase Ib/II Study of Sitravatinib Alone or With Tislelizumab in Advanced Hepatocellular Carcinoma and Gastric Cancer/Gastroesophageal Junction Cancer,” Cancer Immunology, Immunotherapy: CII 73, no. 11 (2024): 219.

[214] T. W. Kim, S. H. Kim, H. J. Do, et al., “The Role of Axl Inhibition and Immune Checkpoint Blockade in Non-Small Cell Lung Cancer: Current Understanding and Treatment Strategies,” Cancer Diagnosis & Prognosis 5, no. 4 (2025): 417–428.

[215] K. C. Allison and L. S. Page, “Inhibiting Efferocytosis Reverses Macrophage-Mediated Immunosuppression in the Leukemia Microenvironment,” Frontiers in Immunology 14 (2023): 1146721.

[216] N. Nishida-Aoki and T. S. Gujral, “Polypharmacologic Reprogramming of Tumor-Associated Macrophages Toward an Inflammatory Phenotype,” Cancer Research 82, no. 3 (2022): 433–446.

[217] N. J. Lakhani, L. Q. M. Chow, J. F. Gainor, et al., “Evorpacept Alone and in Combination With Pembrolizumab or Trastuzumab in Patients With Advanced Solid Tumours (ASPEN-01): A First-in-Human, Open-Label, Multicentre, Phase 1 Dose-Escalation and Dose-Expansion Study,” Lancet Oncology 22, no. 12 (2021): 1740–1751.

[218] Y. Liu, Y. Wang, Y. Yang, et al., “Emerging Phagocytosis Checkpoints in Cancer Immunotherapy,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 104.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.